Other Information
−Removed: Effective as of November 4, 2024, the Board of Directors of Co-Diagnostics,
−Removed: (the “Company”), approved an amendment (the “Amendment”) to the Company’s Amended and Restated Bylaws
−Removed: (the “Bylaws”).
−Removed: The Amendment modifies the Company’s Bylaws to eliminate the classification of the Board of Directors
−Removed: and provide that all members of the Board of Directors are elected annually.
−Removed: The Amendment also makes various conforming changes to the
−Removed: Bylaws to reflect the de-classification of the Board of Directors.
−Removed: The foregoing summary of the Amendment is qualified in its entirety
−Removed: by reference to the full text of the Amendment, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.
−Removed: Amendment to the Amended and Restated Bylaws
Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12 unchanged sentences
Filed herewith.
−Removed: Management Contract or Compensatory Plan or Arrangement
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
1 unchanged sentence
CO-DIAGNOSTICS,
−Removed: November 7, 2024
Executive Officer and Principal Executive Officer
−Removed: November 7, 2024
Financial Officer and Principal Financial and Accounting Officer
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.